chromosome 17 open reading frame 100Genealiases: []
Q-omics provides the consensus-scored C17orf100 profile across patient tissues and cancer cell-line models. C17orf100 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, C17orf100 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, C17orf100 RNA expression shows 19,550 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where C17orf100 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf100 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf100 survival associations across molecular data types. C17orf100 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf100 RNA expression–survival associations across cancer types. High C17orf100 expression shows unfavorable associations in ACC, but favorable associations in UVM, LGG, BRCA, PAAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for C17orf100 RNA expression.
This table summarizes C17orf100 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C17orf100. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf100 shows lower tumor expression in KICH and BRCA and higher tumor expression in BLCA, LUSC, LUAD and KIRP. The BLCA box plot shows higher C17orf100 RNA expression in tumor versus normal tissue (log2 FC = +0.851, t-test p < 0.001).
This table shows molecular features associated with C17orf100 in patient tissues and cancer cell lines. In patient samples, C17orf100 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf100 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
